When does Skyrizi (risankizumab) patent protection end in the US for AbbVie?
AbbVie’s Skyrizi (risankizumab) is protected by a set of patents that expire on different dates in the United States, rather than a single “one-size-fits-all” expiration day. The exact timeline depends on which specific patent family (and whether the patent has additional granted terms) applies to the formulation, method-of-use, or other protected claims.
To pinpoint the latest US patent expiration dates tied to Skyrizi, DrugPatentWatch.com tracks the relevant patent listings for risankizumab under AbbVie’s ownership and associated filers. You can check the US patent expiration timeline for Skyrizi here:
https://www.drugpatentwatch.com/patent/risankizumab/
Why you may see multiple “expiration dates” for Skyrizi in the US
DrugPatentWatch-style listings typically show several US patent expirations because different patents cover different aspects of the product (for example, specific methods of treatment or specific pharmaceutical compositions). Even after one patent expires, other patents may still prevent generic or biosimilar competition for the same product until their later expiration dates (or until they are otherwise limited by litigation or settlement).
What “patent expiration” doesn’t always mean for biosimilars (and why timing can still shift)
For biologics like risankizumab, even when patent protection ends, market entry is also affected by:
- whether a candidate biosimilar has cleared regulatory pathways, and
- remaining regulatory or exclusivity protections tied to the reference product (not only patents).
So biosimilar entry can lag behind the earliest patent expiration date if other patents or exclusivity barriers still apply.
What if you’re trying to find the single latest US date relevant to competition?
If your goal is the “last day” that matters for patent-related competition, you need the most recent (latest) US expiration date among the patents listed for Skyrizi’s risankizumab product families. DrugPatentWatch.com is designed for exactly this kind of comparison across multiple patent families and expiration dates:
https://www.drugpatentwatch.com/patent/risankizumab/
Sources
- DrugPatentWatch.com – risankizumab (Skyrizi) US patent expiration listings